Report Information More information from: https://www.wiseguyreports.com/reports/1184709-mild-cognitive-impairment-pipeline-review-h1-2017 Mild Cognitive Impairment - Pipeline Review, H1 2017 Report / Search Code: WGR1184709 Publish Date: 11 April, 2017 Price 1-user PDF : $ 2000.0 Site PDF : $ 4000.0 Enterprise PDF : $ 6000.0 Description: Mild Cognitive Impairment - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H1 2017, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape. Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mild Cognitive Impairment - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 8, 7, 1, 13, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively. Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Contents: Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Mild Cognitive Impairment - Overview Mild Cognitive Impairment - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Mild Cognitive Impairment - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Mild Cognitive Impairment - Companies Involved in Therapeutics Development AgeneBio Inc Avraham Pharmaceuticals Ltd CereSpir Inc ConSynance Therapeutics Inc Eisai Co Ltd Eli Lilly and Company Ensol Biosciences Inc Genzyme Corp IntelGenx Corp Krenitsky Pharmaceuticals Inc Merck & Co Inc Nanotherapeutics Inc Neuron Biopharma SA NLS Pharma Group Octapharma AG Pfizer Inc Sage Therapeutics Inc SBI Pharmaceuticals Co Ltd Suven Life Sciences Ltd Takeda Pharmaceutical Company Ltd Therapix Biosciences Ltd Mild Cognitive Impairment - Drug Profiles aminolevulinic acid hydrochloride - Drug Profile BAN-2401 - Drug Profile
bosutinib - Drug Profile brexanolone - Drug Profile CSP-1103 - Drug Profile CSTI-200 - Drug Profile DAOI-B - Drug Profile dronabinol - Drug Profile elenbecestat - Drug Profile immune globulin (human) - Drug Profile KP-544 - Drug Profile ladostigil tartrate - Drug Profile levetiracetam - Drug Profile levofacetoperane - Drug Profile LY-3002813 - Drug Profile LY-3303560 - Drug Profile montelukast sodium - Drug Profile Moriah-1000 - Drug Profile NPS-0158 - Drug Profile
NPS-0163 - Drug Profile NST-0037 - Drug Profile NST-0076 - Drug Profile NST-0078 - Drug Profile NTC-942 - Drug Profile Peptides to Agonize Insulin Receptor for Mild Cognitive Impairment and Alzheimer's Disease - Drug Profile sargramostim - Drug Profile Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile SUVN-501 - Drug Profile SUVN-502 - Drug Profile SUVN-507 - Drug Profile SUVN-512 - Drug Profile SUVNI-1307014 - Drug Profile TAK-071 - Drug Profile tropisetron - Drug Profile verubecestat - Drug Profile XEN-107 - Drug Profile
Mild Cognitive Impairment - Dormant Projects Mild Cognitive Impairment - Discontinued Products Mild Cognitive Impairment - Product Development Milestones Featured News & Press Releases Oct 31, 2016: Therapix Biosciences Successfully Completed the Development of a Formulation for a Tablet for Sublingual Administration of THC for Pharmaceutical Use Aug 22, 2016: IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain Jul 13, 2016: IntelGenx to Initiate Phase 1 Trial of Montelukast Jul 28, 2015: Avraham Pharmaceuticals Announces Successful Second Interim Results in Phase 2b Study of Ladostigil for the Treatment of Mild Cognitive Impairment Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment Apr 14, 2010: Alzheimer Drug Co Avraham Pharmaceuticals Raises $9m Jul 27, 2009: Suven Presented Positive Phase-I Clinical Data Of SUVN-502 For Alzheimer s Disease At ICAD 2009, Vienna, Austria. Apr 09, 2009: Suven Completes Phase I Clinical Trials Multiple Ascending Dose Of SUVN-502 In Switzerland Oct 13, 2008: Suven Announces That SUVN-502 Data Is Being Presented At 16th BioPartnering In London Sep 29, 2008: Suven Completes Phase-I Clinical Trials Single Ascending Dose Of Suvn-502 In Switzerland Sep 25, 2008: Suven Life Sciences Ltd. Announces DCGI Nod To Conduct Phase-I Clinical Trials Of Suvn-502 For Alzheimer S Disease Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer List of Tables Number of Products under Development for Mild Cognitive Impairment, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Mild Cognitive Impairment - Pipeline by AgeneBio Inc, H1 2017 Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd, H1 2017 Mild Cognitive Impairment - Pipeline by CereSpir Inc, H1 2017 Mild Cognitive Impairment - Pipeline by ConSynance Therapeutics Inc, H1 2017 Mild Cognitive Impairment - Pipeline by Eisai Co Ltd, H1 2017 Mild Cognitive Impairment - Pipeline by Eli Lilly and Company, H1 2017 Mild Cognitive Impairment - Pipeline by Ensol Biosciences Inc, H1 2017 Mild Cognitive Impairment - Pipeline by Genzyme Corp, H1 2017
Mild Cognitive Impairment - Pipeline by IntelGenx Corp, H1 2017 Mild Cognitive Impairment - Pipeline by Krenitsky Pharmaceuticals Inc, H1 2017 Mild Cognitive Impairment - Pipeline by Merck & Co Inc, H1 2017 Mild Cognitive Impairment - Pipeline by Nanotherapeutics Inc, H1 2017 Mild Cognitive Impairment - Pipeline by Neuron Biopharma SA, H1 2017 Mild Cognitive Impairment - Pipeline by NLS Pharma Group, H1 2017 Mild Cognitive Impairment - Pipeline by Octapharma AG, H1 2017 Mild Cognitive Impairment - Pipeline by Pfizer Inc, H1 2017 Mild Cognitive Impairment - Pipeline by Sage Therapeutics Inc, H1 2017 Mild Cognitive Impairment - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2017 Mild Cognitive Impairment - Pipeline by Suven Life Sciences Ltd, H1 2017 Mild Cognitive Impairment - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Mild Cognitive Impairment - Pipeline by Therapix Biosciences Ltd, H1 2017 Mild Cognitive Impairment - Dormant Projects, H1 2017 Mild Cognitive Impairment - Dormant Projects, H1 2017 (Contd..1), H1 2017 Mild Cognitive Impairment - Discontinued Products, H1 2017 List of Figures Number of Products under Development for Mild Cognitive Impairment, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Number of Products by Top 10 Targets, H1 2017 Number of Products by Stage and Top 10 Targets, H1 2017 Number of Products by Top 10 Mechanism of Actions, H1 2017 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 Number of Products by Routes of Administration, H1 2017 Number of Products by Stage and Routes of Administration, H1 2017 Number of Products by Molecule Types, H1 2017 Number of Products by Stage and Molecule Types, H1 2017 wiseguyreports.com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349